Development of crescentic membranoproliferative glomerulonephritis after COVID-19 vaccination

Gabor Göndör; Sara H Ksiazek; Heinz Regele; Andreas Kronbichler; Maarten Knechtelsdorfer; Marcus D Säemann

doi:10.1093/ckj/sfac222

Development of crescentic membranoproliferative glomerulonephritis after COVID-19 vaccination

Clin Kidney J. 2022 Oct 19;15(12):2340-2342. doi: 10.1093/ckj/sfac222. eCollection 2022 Dec.

Authors

Gabor Göndör¹, Sara H Ksiazek¹, Heinz Regele², Andreas Kronbichler³, Maarten Knechtelsdorfer¹, Marcus D Säemann^{1

4}

Affiliations

¹ Department of Medicine VI with Nephrology and Dialysis, Clinic Ottakring, Vienna, Austria.
² Department of Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
³ Department of Medicine, University of Cambridge, Cambridge, UK.
⁴ Medical School, Sigmund Freud University, Vienna, Austria.

Abstract

Membranoproliferative glomerulonephritis (MPGN) comprises a histologic pattern of glomerular injury with different underlying diseases. Here we report on a 47-year-old female with rapidly progressive glomerulonephritis (RPGN) on top of a previously diagnosed idiopathic MPGN after receiving the first dose of the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) mRNA vaccine. After aggressive immunosuppression her serum creatinine returned to normal values, along with reduction of proteinuria. Recently, numerous publications have reported an association of glomerular diseases with COVID-19 vaccination. Our case presents to the best of our knowledge the first occurrence of possible association of COVID-19 mRNA vaccination with a crescentic form of MPGN.

Keywords: AKI; COVID-19; membranoproliferative glomerulonephritis; nephrotic syndrome; vaccination.

Publication types

Case Reports